Close Menu

NEW YORK — Australian molecular diagnostics firm Genetic Technologies said on Thursday that it has signed definitive agreements to sell $5.1 million worth of its American Depository Shares (ADSs) to institutional investors.

Through the direct offering, the Genetic Technologies will sell 1,025,000 ADSs at $5 apiece. Each ADS, the company said, represents 600 of its ordinary shares. The transactions are expected to close on or around July 20.

HC Wainwright is the exclusive placement agent for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature survey finds a high level of support among scientists for former Vice President Joe Biden in the upcoming US election.

Two coronavirus vaccine trials that had been paused in the US have resumed.

The Scientist reports the physician behind Surgisphere inactivated his medical license in one state and received one in another.

In PLOS this week: analysis of link between somatic copy number and telomere length, sequencing study of individuals with gallbladder S. Typhi colonization, and more.

Oct
28
Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.